Talaria
Talaria
chasing medical miracle
About us
Talaria Inc., former Gaea APAC Inc., renewed and reorganized teams with clinical trial specific service on 2024.
History
2024- Current
Talaria renamed
Rename and service as Talaria
Reorganized team for full service Clinical Research
2022-2023
growth of business
involve gorvenment service
Dr. Charles JH Kim, CEO was appointed a reviewer and member of Korea Institute of Drug Safety and Risk Management (KIDS) and Medical Device Consulting Council (MDCC) at Korea Health Industry Development Institute (KHIDI)
2021
establishment of Gaea APAC Inc.
Full service CRO named Gaea APAC Inc. established on May 2021, a proud member of Gaea OU (EU based).
Talaria services
From Laboratory To clinic
Talaria offers a broad range of customized services to support Pharma, biotech and medical device companies to bring new drugs and devices to market approval faster
Consulting
Talaria's consulting service provides strategic analysis to support and conduct best solution in drug and device development
Safety Solutions
Safety and adverse event causality assessment with Talaria's own safety assessment system (Korea Patent 10-2507211)
Clinical Operations
Talaria provides a range of integrated service that cover the feasibility, CTC approval, project management and execution and analysis of clinical trial
Patient care service
After clinical ends, patients who need
IMP (or ID) treatment of disease.
We can provide and assisst Compassionate Use (or Expanded Access Program) in Korea
what makes difference?
Contact Us
Address
2F 21, Tehelan road 128,
Gangnam gu, Seoul, Korea
Opening Hours
Mon - Fri: 9am - 6pm
Saturday / Sunday: Closed
National holiday: Closed
Contact
+82-70 4506 9110
info@talaria.im